Efficacy and safety of aspirin and clopidogrel in the treatment of coronary heart disease in the elderly
阿司匹林和氯吡格雷对老年冠心病的治疗效果及安全性观察

摘要

目的 探讨临床治疗老年冠心病使用阿司匹林和氯吡格雷的临床疗效及安全性。方法 将2022年3月~2024年3月内郁南县第二人民医院就诊的老年冠心病患者180例为试验开展对象，按照治疗方式分为对照组（阿司匹林）和观察组（加用氯吡格雷）各90例，以治疗前后的炎性因子水平和并发症发生率等指标对比两组治疗效果。结果 治疗前，两组白细胞介素-6（IL-6）、C反应蛋白（CRP）等炎性因子水平对比无统计学意义，（P＞0.05）。治疗后，观察组炎性因子和并发症概率优于对照组，差异均有统计学意义（P＜0.05）。结论 在老年冠心病患者的药物方案应用中，使用阿司匹林与氯吡格雷的治疗方案能够取得更好疗效，能减少炎症发生概率，提高治疗效果，同时用药安全性也更高，具有较高使用价值。

Abstract

Objective: to investigate the clinical efficacy and safety of aspirin and clopidogrel in the treatment of elderly patients with coronary heart disease.
Methods: from March 2022 to March 2022,180 elderly patients with coronary heart disease were 2024 in the second people's Hospital of Yunan County, they were divided into control group (aspirin) and observation group (add-on clopidogrel) according to the treatment mode. The levels of inflammatory factors and the incidence of complications before and after treatment were compared between the two groups.
Results: before treatment, there was no significant difference in the levels of inflammatory factors such as IL-6 and CRP between the two IL6 groups (P > 0.05) . After treatment, the inflammatory factors and the probability of complications in the observation group were better than those in the control group (p < 0.05).
Conclusion  : aspirin and clopidogrel are more effective in the treatment of elderly patients with coronary heart disease, which can reduce the probability of inflammation and improve the therapeutic effect, at the same time, the safety of drug use is also higher, with higher use value.